AUPH - auriniapharma.com Market Value to Book Value Ratio
The protection of rights for its nephritis drug and strong influence within US medicine create a robust barrier for competitors, as confirmed by this price chart where the metric stands at 3.70. Aurinia Pharmaceuticals (AUPH) generates revenue from supplying Lupkynis to clinics for the therapy of autoimmune pathologies. However, total reliance on this single product without portfolio expansion poses serious financial threats.
Aurinia Pharmaceuticals Inc (AUPH) - metric breakdowns and financial figures
- share price and expert price forecast:
- market capitalization statistics:
- book capitalization data:
- debt obligations and liquidity statistics:
Debt to Equity Aurinia Pharmaceuticals|AUPH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Aurinia Pharma|AUPH - Company Total Debt|Debts to Book Capitalization Aurinia Pharma|AUPH - Company Long-Term Debts|Company Current Liabilities Aurinia Pharmaceuticals|Quick Ratio auriniapharma.com
- earnings and valuation multiples indicators:
Basic company analysis:Aurinia Pharmaceuticals - AUPH
Aurinia Pharmaceuticals (AUPH) demonstrates low sensitivity to external shocks, supported by increasing insurance coverage and an expanding patient base for lupus nephritis. By analyzing the price-to-book ratio, investors can assess the market price premium over net assets, allowing them to determine the direction of equity revaluation and capture demand momentum before a trend reversal.
Competitor analysis
ARGX: Market Capitalization to Book Value Ratio|biontech.de - Market Value to Book Value|Market Value to Book Value Ratio abivax.com|ADMA Biologics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PTGX|IMVT (Immunovant Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|Market Capitalization to Book Value Ratio grifols.com GRFS|ADPT - Market Value to Book Value Ratio|Market Value to Book Value CLDX (Celldex Therapeutics Inc)|BioCryst Pharmaceuticals Inc (BCRX) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Vera Corp|DNTH (Dianthus Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pharvaris.com|Market Cap to Net Assets Ratio ABCL (AbCellera Bio)|TRML (Tourmaline Bio Inc) - Market Value to Book Value|Market Capitalization to Book Value Ratio PGEN (Intrexon)|Market Capitalization to Book Value Pharming Corp (PHAR)|NKTR - Market Value to Book Value Ratio|upstreambio.com (UPB) - Market Cap to Net Assets Ratio|Zenas Biopharma (ZBIO) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|Market Cap to Net Assets Ratio GOSS|Market Capitalization to Book Value Ratio KalVista Corp|Market Value to Book Value Ratio Septerna Inc (SEPN)|pieris.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio SVRA (Savara)|Rigel Pharma (RIGL) - Market-to-Book Ratio|AnaptysBio Corp - Market Capitalization to Book Value Ratio|ATXS - Market Capitalization to Book Value Ratio|ENGN (enGene Holdings Inc.) - Market Cap to Net Assets Ratio|rapt.com (RAPT) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Aerovate Therapeutics, Inc.|ACRS: Market Value to Book Value|Market Capitalization to Book Value Ratio KYTX|Market Capitalization to Book Value Tiziana Life Sciences, Ltd.|Market Value to Book Value Ratio Cabaletta Bio, Inc. CABA|VTYX: Capitalization to Book Value Ratio|Theratechnologies - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Avalo Therapeutics, Inc. AVTX|ELDN: Market Capitalization to Book Value Ratio|Agenus, Inc (AGEN) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio CLYM|ZURA: Market Value to Book Value|Market Value to Book Value Ratio aTyr Pharma (ATYR)|ADAG: Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio IMA (Ikena Oncology)|Market Value to Book Value STTK|Equillium Bio - Market Capitalization to Book Value Ratio|CNTB - Market Capitalization to Book Value Ratio|immunic-therapeutics.com (IMUX) - Market Value to Book Value Ratio|Atara Bio - Market Value to Book Value|Market Value to Book Value Ratio InflaRx NV|Market Cap to Net Assets Ratio X4 Pharmaceuticals, Inc (XFOR)|Market Capitalization to Book Value Ratio ACET|Market Capitalization to Book Value Ratio celularity.com (CELU)|Market Capitalization to Book Value Ratio INMB (INmune Bio)|BRNS - Market Cap to Net Assets Ratio|Kezar Life Sciences, Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio SAB Biotherapeutics Inc|AKTX (Akari Therapeutics) - Market Cap to Net Assets Ratio|Enlivex Therapeutics Ltd. (ENLV) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio QTTB|GOVX (GeoVax Labs) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio EDSA|Market Capitalization to Book Value iBio Corporation|Market Capitalization to Book Value Ratio CARM (Carisma Therapeutics Inc.)|XTLB - Market Cap to Net Assets Ratio|Bolt Bio - Market Capitalization to Book Value Ratio|HCWB - Market Capitalization to Book Value Ratio|aptevotherapeutics.com (APVO) - Market Value to Book Value Ratio|AIM (aimimmuno.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Aditxt Inc.|gribio.com (GRI) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio XRTX|Market Capitalization to Book Value Ratio Vyome Holdings Inc. (HIND)|Revelation Bio - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Indaptus Corp INDP|SCNI - Market Value to Book Value Ratio|Market Capitalization to Net Assets CALI|AFMD: Market Capitalization to Book Value Ratio|Allakos - Market Value to Book Value|Market Value to Book Value Ratio HOOKIPA Pharma, Inc.|IGM Bio - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio ITOS|OCEA (oceanbiomedical.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio TCBP (TC BioPharm)|Market Capitalization to Book Value Ratio Third Harmonic Bio Inc. THRD